Scleroderma is a chronic connective tissue disease that affects an estimated 300,000 people within the United States, according to the National Women’s Health Information Center. The disease is commonly associated with excessive collagen that narrows blood vessels, restricting the flow of blood to body tissues and organs and severely limiting the movement of patients’ fingers and hands. Cytori Therapeutics, Inc. (NASDAQ: CYTX) is addressing this critically underserved medical need through the continued development of ECCS-50.

ECCS-50 utilizes Cytori’s proprietary Cell Therapy™ technology, which has been shown to improve blood flow, modulate the immune system and facilitate wound repair. As a same-day treatment option using a clinical-grade preparation of the patient’s own readily available cells, the company’s technology has demonstrated a significant therapeutic impact on both acute and chronic conditions, making its scleroderma indication particularly intriguing for prospective shareholders.

In the first quarter of 2015, Cytori took a major step in the development of ECCS-50 by gaining full approval for a pivotal phase III trial for the treatment of hand dysfunction associated with scleroderma. This clinical study, which is expected to initiate enrollment in the coming weeks, headlines an extremely promising development pipeline that currently features two late-stage U.S. trials, as well as two advanced programs in international markets.

The company’s actions in recent months have focused on securing the required capital to continue development of its drug candidates. In June, the company announced a restructured debt agreement that significantly reduced its interest rate while providing repayment deferral options that will allow Cytori to more efficiently pursue development milestones.

“The restructured loan considerably reduces our near-term financing cash obligations and… significantly strengthens our balance sheet,” Tiago Giaro, chief financial officer of Cytori, stated in a news release. “We are now laser-focused on the execution of our key clinical objectives with continued emphasis on our… U.S. pivotal phase III scleroderma clinical trials.”

Moving forward, Cytori will continue to progress with the development of its leading product candidates. Look for the company to advance enrollment of its highly-anticipated scleroderma trial in the weeks to come, clearing the way for the initiation of its phase III study in the near future.

For more information, visit www.cytori.com

The Singing Machine Company, the North American leader in consumer karaoke entertainment systems, is ushering in the next iteration of karaoke technology through the upcoming release of its new Digital Download line of products. Scheduled for launch this fall, the Digital Download lineup will introduce a host of new features designed to take the classic singing experience to the next level – including high-definition karaoke videos, a downloadable library featuring more than 10,000 songs, a preloaded flash drive to store songs and recordings, and an intuitive custom playlist creator.

Upon release, SMDM’s innovative new product line will be available nationwide through the company’s industry-leading distribution partners, such as Toys ‘R’ Us, Sam’s Club and Costco. By integrating support for Bluetooth™ audio streaming and the Singing Machine Mobile Karaoke App, which is available on iOS, SMDM will look to expand its market share in the consistently performing entertainment market.

“[W]e are continuing to evolve our products to incorporate the latest technology to improve the karaoke experience and promote access to music through karaoke downloads and streaming,” Gary Atkinson, chief executive officer of SMDM, stated in a news release. “We believe this will increase our product’s appeal to a wider consumer demographic and create new revenue streams to the company.”

In recent years, the company has utilized this strategy to great success, recording consistent financial growth. During its fiscal year ending March 2015, SMDM’s karaoke systems were stocked in more than 10,000 storefronts throughout North America, leading to more than one million sold units. In total, the company realized a 25 percent year-over-year increase in net sales for the period on the way to its fourth consecutive fiscal year of profitability.

SMDM has leveraged the timeless popularity of the consumer karaoke market to promote favorable returns for well over three decades. As one of the first companies to provide these systems for home entertainment in the United States, SMDM has built a collection of recognizable, trusted brands within the niche market – including The Singing Machine®, SoundX®, Home™ and SMDigital™.

For more information, visit www.singingmachine.com

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medications. Utilizing its proprietary BioErodible MucoAdhesive (BEMA®) drug delivery technology, the company is developing new applications of proven therapies aimed at addressing important unmet medical needs. By building upon previously approved therapeutics, BDSI is able to adhere to a more time-efficient regulatory pathway, effectively shortening the development process and providing a streamlined method for the company to pursue its ultimate goal of enhancing patient care.

The company’s product portfolio includes two unique treatment options currently approved for commercialization – ONSOLIS®, for the treatment of breakthrough cancer pain, and BUNAVAIL™, for the treatment of opioid dependence. In the first quarter of 2015, BDSI made significant progress with both of these products. In particular, BUNAVAIL recorded a 25 percent month-over-month growth average in prescription sales throughout the period, and the company reacquired North American marketing rights for ONSOLIS, clearing the way for future commercialization.

“We continue to make progress with the launch of BUNAVAIL,” Dr. Mark A. Sirgo, president and chief executive officer of BDSI, stated in a news release. “[W]e are making significant advancements in securing managed care and pharmacy access to BUNAVAIL… providing additional access to over 30,000 prescriptions each month.”

Through the ongoing launch of BUNAVAIL, BDSI gains access to a large and significantly underserved market within the U.S. pharmaceutical industry. According to the U.S. Department of Health and Human Services, approximately 2.5 million people throughout the country are currently dependent on prescription opioids. As a result, the current market for the treatment of opioid dependence was estimated at $1.7 billion in 2013, demonstrating the considerable market potential of BUNAVAIL.

In May, BDSI took a major step toward capitalizing on this potential through the expansion of its sales and managed markets teams. Through these hires, the company added valuable sales and managed markets experience that’s expected to drive substantial growth in both sales and market share in the months to come.

“We are extremely pleased to have hired a number of key sales and managed markets personnel previously with Salix, a leader in its respective field and one driven by a strong commercial sales organization,” continued Sirgo. “This provides us with a strong sales and managed markets leadership team as we continue to advance the commercialization of BUNAVAIL.”

For prospective shareholders, BDSI’s favorable product pipeline should provide a platform for sustainable market growth in the future. Look for the company to leverage this positioning in order to promote strong returns moving forward.

For more information, visit www.bdsi.com

FastFunds Financial Corp., through wholly-owned subsidiaries Cannabis Angel, Inc. and The 420 Development Corporation, is focused on the acquisition and development of revenue-producing entities that provide ancillary services to the cannabis industry. In 2014, FastFunds entered into the financial services sector through the acquisition of 49 percent of Cannabis Merchant Financial Solutions, Inc. (CMFS). Through this subsidiary, the company has developed one of its most intriguing offerings, the Tommy Chong Green Card.

The Tommy Chong Green Card is a specially-developed reloadable stored value card with a rewards feature aimed at the burgeoning cannabis industry. Through this product, the company will gain access to both the rapidly expanding recreational marijuana market and the multi-billion dollar gift card vertical. In recent weeks, FastFunds has focused on developing a distribution network for its unique product. Earlier this month, the company took a significant step toward achieving national distribution by signing a sales representation agreement with Evergreen Licensing of Northridge, California. This deal is expected to provide FastFunds with access to approximately 300 dispensaries throughout the Golden State.

“The signing of a sales representative agreement with Evergreen is a major step in our goal for national distribution of the Tommy Chong Green Card,” Kurt Martig, president of CMFS, stated in a news release. “California is significant as it is one of the largest states in terms of dollar volume of sales and the number of operating dispensaries.”

In addition to its distribution efforts, FastFunds is currently planning a social media launch for the product ahead of next year’s presidential elections. With this strategy, the company will look to capitalize on the potential for more widespread cannabis legalization, which is currently being forecast by many industry analysts. Through its association with celebrity actor Tommy Chong, the company expects to gain access to more than 4.5 million social media followers upon its upcoming launch, helping it differentiate the Tommy Chong Green Card from similar products.

“The market for legal cannabis is one of our nation’s fastest growing industries; the momentum is nothing short of astounding,” stated Henry Fong, president and chief executive officer of FastFunds. “Our focus is to quickly and efficiently take advantage of the profound opportunities this growth provides and increase shareholder value.”

For prospective shareholders, the company’s growing presence in an incredibly high-potential industry makes it an intriguing investment opportunity moving forward. FastFunds will be looking to continue building on its recent progress with the Tommy Chong Green Card, as well as its numerous projects through its remaining subsidiaries, in order to promote strong financial growth and sustainable returns in the months to come.

For more information, visit www.fastfundsfinancial.com

Let us hear your thoughts: Fastfunds Financial Corp. Message Board

Definitive Rest Mattress Company is headed in a new direction focused on providing customers with innovative solutions to meet their manufacturing needs. Following the company’s January acquisition of NU Metals Technology, DRMC has made considerable progress toward expanding its presence in the potentially lucrative metal sales and CNC manufacturing industries. Through these efforts, the company plans to promote significant industry growth while maximizing shareholder value in the future.

In June, DRMC highlighted the early results of its transition when it announced positive sales projections. According to the company’s news release, it is on pace to meet revenue projections for the third quarter of 2015, with its new product line opening the door for continued expansion into a collection of market sectors – including the aerospace, defense and commercial component manufacturing industries.

“Recent orders from Asia and domestic companies for stainless and aluminum have set the tone for NU Metals Technology,” Juan Carlos Murga, president and chief executive officer of DRMC, stated in a news release. “By securing orders until the end of 2015, our future is solid moving forward. With new business partners, new company direction and a new mindset, our shareholders will be happy to see DRMC sales activity on the next quarterly report.”

Building on these strong results, DRMC recently announced the addition of carbon fiber technology to its line of advanced manufacturing products and services. This move will give the company access to a market that is forecast to achieve an annual growth rate of 17 percent over the next five year, reaching an estimated market value of $7.3 billion by 2017. In particular, carbon fiber technology is expected to give DRMC an improved position relative to the automotive, aircraft and aerospace industries.

“We want to stay in the forefront of evolving technology, and carbon fiber is part of the future,” continued Murga. “Based on growth rate percentages for 2017… carbon fiber technology is here to stay.”

In the coming weeks, DRMC is expected to complete its metamorphosis into a metals and machine tool operations company by announcing a new corporate name to reflect its updated business operations. Additionally, the company plans to launch its new website by the end of July. As DRMC leaves its old operations behind and looks forward, it’s in a strong strategic position to promote substantial industry growth and sustainable returns for the foreseeable future. For prospective shareholders, this market potential makes DRMC an intriguing investment opportunity moving forward.

For more information, visit www.numetalstech.com

Definitive Rest Mattress Company is headed in a new direction focused on providing customers with innovative solutions to meet their manufacturing needs. Following the company’s January acquisition of NU Metals Technology, DRMC has made considerable progress toward expanding its presence in the potentially lucrative metal sales and CNC manufacturing industries. Through these efforts, the company plans to promote significant industry growth while maximizing shareholder value in the future.

In June, DRMC highlighted the early results of its transition when it announced positive sales projections. According to the company’s news release, it is on pace to meet revenue projections for the third quarter of 2015, with its new product line opening the door for continued expansion into a collection of market sectors – including the aerospace, defense and commercial component manufacturing industries.

“Recent orders from Asia and domestic companies for stainless and aluminum have set the tone for NU Metals Technology,” Juan Carlos Murga, president and chief executive officer of DRMC, stated in a news release. “By securing orders until the end of 2015, our future is solid moving forward. With new business partners, new company direction and a new mindset, our shareholders will be happy to see DRMC sales activity on the next quarterly report.”

Building on these strong results, DRMC recently announced the addition of carbon fiber technology to its line of advanced manufacturing products and services. This move will give the company access to a market that is forecast to achieve an annual growth rate of 17 percent over the next five year, reaching an estimated market value of $7.3 billion by 2017. In particular, carbon fiber technology is expected to give DRMC an improved position relative to the automotive, aircraft and aerospace industries.

“We want to stay in the forefront of evolving technology, and carbon fiber is part of the future,” continued Murga. “Based on growth rate percentages for 2017… carbon fiber technology is here to stay.”

In the coming weeks, DRMC is expected to complete its metamorphosis into a metals and machine tool operations company by announcing a new corporate name to reflect its updated business operations. Additionally, the company plans to launch its new website by the end of July. As DRMC leaves its old operations behind and looks forward, it’s in a strong strategic position to promote substantial industry growth and sustainable returns for the foreseeable future. For prospective shareholders, this market potential makes DRMC an intriguing investment opportunity moving forward.

For more information, visit www.numetalstech.com

GrowBLOX Sciences, a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, today announced that over the course of the next few weeks it will implement certain changes in management personnel and operating procedures in preparation for the commencement of cultivation operations through its majority-owned subsidiary, GB Sciences Nevada, LLC.

“The build out of our principal cultivation facility in Nevada is proceeding well and on schedule. As we transition from our engineering intensive development stage, involving largely R&D and licensure efforts, to the day-to-day operations of producing an excellent product, branding it appropriately, and maximizing our revenue, we will need to significantly beef up our staff,” CEO Craig Ellins stated in the news release. “We have brought in John Poss as a consultant to put in effect some of these changes. We feel that John will be instrumental in helping us to achieve that transition smoothly and expeditiously.”

John Poss, a former CPA, is a senior executive with a track record of improving performance in technology, logistics, operations, business systems and finance. His experience includes CEO, COO, CFO and CTO of both public and private companies with sales ranging from $10 million to $450 million as well as over 15 years of consulting experience. He also has extensive M&A experience, both buy and sell side, including private equity. He also holds two United States patents.

The company also plans to appoint a general manager for the GBS Nevada Venture in the near future, as well as support staff for the 30,000-square-foot cultivation facility. Key personnel for the retail location in Las Vegas as well as the delivery service will also be put in place in the upcoming weeks. Product development and scientific validation of consumer facing products will be managed by a combination of in-house scientists and contracted chemists and formulators.

“Our drug discovery strategy and clinical research will be enhanced by the success of our Nevada operations. Profiling proprietary strains for their therapeutic properties is essential for the scientific and medical evolution of cannabis. Our competitive advantage lies in the privilege to legally grow and scientifically study medical cannabis here in Nevada. It is extremely important to our shareholders that we have the ability to test and develop products on a commercial scale but with laboratory precision,” said Chief Science Officer Dr. Andrea Small-Howard.

In conjunction with the aforementioned changes, GBLX has replaced its PCAOB auditor with Patrick Heyn, CPA, who was the concurring auditor for the company’s most recent audited statement. GBLX expects to shortly announce further additions of key personnel to manage the revenue-producing operations expected to begin in the early fourth quarter of 2015.

For more information, visit www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

NXT-ID, Inc. (NASDAQ: NXTD) is a biometric authentication company focused on the growing mobile commerce market. Founded in 2011, the company has an established portfolio of technology patents and biometric security solutions, including Wocket®, a next-generation smart wallet designed to replace all of customers’ credit cards without the need for a mobile phone. In addition to credit cards, NXT-ID’s innovative product offers consumers the means to protect a wide array of payment and personal information – including debit, loyalty, gift, ID, membership, insurance, medical information and passwords.

“Wocket acts as a personal vault for all your cards and identification information,” Gino Pereira, chief executive officer of NXT-ID, stated in a news release. “Wocket addresses convenience like few other competitive technologies with its ability to store thousands of cards and the fact that it can be used at almost all point of sale readers, something mobile apps cannot do.”

Identity theft occurs every 45 seconds in the United States, and, in 2012, the total costs associated with this theft grew to more than $24.7 billion, according to the Federal Trade Commission. Among these crimes, an estimated 43 percent stemmed from lost or stolen wallets, according to a report by Javelin Strategy & Research, further demonstrating the potential benefits of NXT-ID’s groundbreaking payment solution. With most identity theft protection services only springing into action after theft has occurred, the company’s revolutionary proactive approach could help to establish it as a major player in a potentially massive market segment.

In recent months, NXT-ID has continued preparing for the future of technology by aggressively expanding upon its intellectual property (IP) portfolio. Earlier this month, the company filed provisional patents for both behavior-directed payments, which covers the use of gesture controls to choose a payment account, and personalized tokenization payments, which allow for the generation of unique, one-time-use tokens that identify both the user and the account without revealing any sensitive information.

“We continue to build out our patent and IP portfolio as the payment industry evolves,” continued Pereira. “It is critical for a technology company like ours to position our technology ahead of the curve.”

AT CES 2015, Wocket was recognized by multiple media outlets as one of the top technology products on display. NXT-ID will look to leverage this momentum as it ramps up commercialization efforts moving forward. Based on its current plans, NXT-ID will continue to scale the rollout of Wocket in the coming months, producing an estimated 30,000 units in the third quarter of this year. When complete, these efforts are expected to provide a platform upon which the company could realize considerable market growth in the future.

For more information, visit www.nxt-id.com

WMIH Corp. (OTCQB: WMIH), through its wholly-owned subsidiary, WM Mortgage Reinsurance Company, Inc., currently engages in runoff mode reinsurance business with respect to mortgage insurance. In 2012, the company emerged from bankruptcy proceedings as the successor to Washington Mutual, Inc. with limited operations outside of its legacy reinsurance business, and, though it has not written any new business since 2008, WMIH still operates its subsidiary’s existing contracts while actively seeking acquisition opportunities across a broad array of industries.

In January, WMIH secured the capital required to fund future acquisitions through the completion of a private offering of 600,000 shares of series B convertible preferred stock. According to the terms of the offering, the newly issued stock will bear dividends on a cumulative basis when declared by the company’s board of directors at an annual rate of three percent. Upon satisfaction of the conversion contingency, all or a portion of the shares will be mandatorily converted into the company’s common stock. If not converted by the mandatory redemption date, remaining shares of series B preferred stock will be automatically redeemed. Net proceeds of the offering were more than $568 million after payment of all offering fees and expenses.

“The completion of the offering of series B preferred stock provides WMIH significant capital to execute on its acquisition strategies,” Michael Willingham, chairman of WMIH, stated in a news release. “With this capital, we intend to continue to pursue opportunities for acquisitions of [businesses] with operations that are complemented by the experience and expertise of our board and management team.”

Among the largest investors in the offering was KKR & Co. L.P., which purchased 200,000 shares of the available stock. This investment followed a similar strategic investment in December 2013, further demonstrating the confidence that the company’s investors place in its seasoned management team.

“We are pleased to participate in the offering and invest additional capital in WMIH, as we continue to see opportunities for the company to grow and diversify its platform,” stated Tagar Olson, head of KKR’s financial services team. “Having partnered with the company for over a year, we believe that WMIH is well positioned as an acquirer and we believe it is capable of leveraging its resources to drive value as it executes on its acquisition strategy.”

For prospective shareholders, an investment in WMIH represents an opportunity to invest in the future. With financing secured to begin its search for a worthwhile acquisition candidate, the company is in a strong position to pivot its operations into a wide variety of potentially lucrative market sectors. Look for WMIH to leverage its current flexibility in order to promote maximized financial returns in the years to come.

For more information, visit www.wmih-corp.com

Rainbow Coral today highlighted substance abuse numbers from the United States and Canada as evidence of Naltrexone’s strong growth potential; the statistics also strengthen RBCC’s plans to aggressively pursue additional partners and distribution channels to get the anti-addiction drug into as many markets as possible.

“Drug and alcohol addiction afflicts millions of North Americans struggling to free themselves from this terrible disease,” RBCC CEO Kimberly Palmer stated in the news release. “The stats don’t paint a pretty picture regarding addiction, however they do represent a window for companies like ours to deliver treatments that will change lives for the better. That’s rewarding from a personal standpoint, and offers an opportunity to build a revenue stream to reward our investors on the business side.”

Wealthy and developed countries like the U.S. and Canada have the world’s highest rates of substance abuse. According to a 2013 survey, 9.4 percent of Americans have used illicit drugs in the past month, up from 8.3 percent in 2002, while approximately 14 million Americans, 7.4 percent of the population, meet the diagnostic criteria for alcoholism. Meanwhile, about 11 percent of Canadians are afflicted with alcohol or drug addiction.

Substance at this level abuse costs U.S. taxpayers USD $700 billion per year for treatment services, employing law enforcement and related equipment. Canadian taxpayers face a C$22.8 billion tab each year to the disease.

RBCC says it is nearing agreements with a Canadian medical group that utilizes Naltrexone to treat substance abuse, as well as with another company to distribute Naltrexone in Canada.

For more information visit www.rainbowsciences.com